Patient Square Capital LP
Patient Square Capital LP reported 23 holdings worth US$646M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 12, 2026
Patient Square Capital LP reported 23 holdings worth US$646M as of Jun 30, 2026. Largest: Roivant Sciences Ltd., Revolution Medicines, Inc. and Mirum Pharmaceuticals, Inc. Filed Aug 12, 2026 (Form 13F).
- Holdings
- 23
- Value as reported
- US$646M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Roivant Sciences Ltd. | 8.02M | US$284M | 44.0% |
| Revolution Medicines, Inc. | 276K | US$51.7M | 8.0% |
| Mirum Pharmaceuticals, Inc. | 261K | US$30.5M | 4.7% |
| Abivax Sa | 207K | US$27.5M | 4.3% |
| Beone Medicines Ltd. Class A | 90,020 | US$25.7M | 4.0% |
| Argenx Se | 23,000 | US$21.3M | 3.3% |
| United Therapeutics Corporation | 37,120 | US$20.1M | 3.1% |
| Cogent Biosciences, Inc. | 425K | US$16.4M | 2.5% |
| Dbv Technologies Sa | 909K | US$14.9M | 2.3% |
| Xenon Pharmaceuticals Inc. | 220K | US$13.3M | 2.1% |
| Arcus Biosciences, Inc. | 356K | US$11M | 1.7% |
| Enliven Therapeutics, Inc. | 213K | US$10.8M | 1.7% |
| Dianthus Therapeutics, Inc. | 108K | US$10.5M | 1.6% |
| Allogene Therapeutics, Inc. | 5.05M | US$10.5M | 1.6% |
| Eyepoint, Inc. | 720K | US$10.3M | 1.6% |
| Arcutis Biotherapeutics, Inc. | 370K | US$9.7M | 1.5% |
| C4 Therapeutics, Inc. | 1.61M | US$7.51M | 1.2% |
| Inventiva Sa | 1.97M | US$7.44M | 1.2% |
| Kymera Therapeutics, Inc. | 47,500 | US$5.45M | 0.84% |
| Sensei Biotherapeutics, Inc. | 175K | US$4.38M | 0.68% |
| Insmed Incorporated | 0 | US$0 | 0.00% |
| Merck & Company, Inc. | 0 | US$0 | 0.00% |
| Nektar Therapeutics | 0 | US$0 | 0.00% |
| Perspective Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Protara Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Spyre Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Assembly Biosciences, Inc. | 0 | US$0 | 0.00% |
| Celcuity Inc. | 0 | US$0 | 0.00% |
| Cytomx Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Definium Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Harrow, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related